Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Docetaxel + Nintedanib & Non-Small-Cell Lung Cancer (NSCLC) (adenocarcinoma), Docetaxel + Nintedanib has an EMA approval in locally advanced, metastatic, or locally recurrent Non-Small-Cell Lung Cancer (NSCLC) (adenocarcinoma) that has progressed after first‑line chemotherapy (1, 2, 3).
The prospective observational trial, identified as NCT02392455 (VARGADO), demonstrated the potential clinical benefit of combining nintedanib with docetaxel for patients who did not respond to previous immune checkpoint inhibitor (ICI) therapy (4).…